Neoadjuvant Lenvatinib and Pembrolizumab for IVC Tumor Thrombus

Abroad (travel likely)RecruitingPHASE2

Conditions

Renal Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

University of Texas Southwestern Medical Center, Dallas, Texas, United States
Contact: Study coordinator (Vitaly Margulis) · vitaly.margulis@utsouthwestern.edu · 214-648-0567
Contact: Study coordinator (MD)

Study leads

Vitaly Margulis, MD
Principal Investigator
University of Texas Southwestern Medical Center

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Diffuse Astrocytoma, IDH-Mutant · Glioblastoma, IDH-wildtype · Brain Metastases, Adult

Abroad (travel likely)RecruitingPHASE1, PHASE2

Beverly Hills, United States · Glendale, United States

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Advanced Solid Tumor · Metastatic Solid Tumor · Soft Tissue Sarcoma (STS)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Scottsdale, United States · Jacksonville, United States

Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma

Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Irvine, United States · Boston, United States

Belzutifan's Role in Active Surveillance Versus Treatment for Indolentmetastatic Clear Cell Renal Ccell Carcinoma (BRAVE-RCC)

Active Surveillance · Clear Cell Renal Cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Houston, United States